Wang C, Chen X, Chen X Y, He Y H
Provincial Clinical Medical College of Fujian Medical University; Department of Pathology, Fujian Provincial Hospital, Fuzhou 350001, China.
Zhonghua Bing Li Xue Za Zhi. 2019 Oct 8;48(10):791-795. doi: 10.3760/cma.j.issn.0529-5807.2019.10.008.
To correlate chromosomal translocations of DUSP22 or TP63 with clinical significance in ALK-negative anaplastic large cell lymphoma (ALK(-)ALCL). Thirty-two patients with ALK(-)ALCL were selected from January 2004 to January 2014 at Fujian Provincial Hospital for the detection of chromosomal translocations of DUSP22 and TP63 by fluorescence in situ hybridization (FISH). The relationship between DUSP22 and TP63 chromosomal translocations and the clinicopathological parameters of ALK(-)ALCL was analyzed. Among the 32 ALK(-)ALCL patients, 7(21.8%) had DUSP22 gene rearrangement (DUSP22(+)ALK(-)ALCL). Three patients (9.4%) had TP63 gene rearrangement (TP63(+) ALK(-)ALCL). There were 22 patients (68.8%) without rearrangement of either DUSP22 or TP63 (DUSP22(-)TP63(-)ALK(-)ALCL). The patients with DUSP22(+) ALK(-)ALCL were among the younger, and the patients with TP63(+) ALK(-)ALCL were among the elder. The mean age of patients with DUSP22(-)TP63(-)ALK(-) ALCL was between those of DUSP22(+)ALK(-)ALCL and TP63(+) ALK(-)ALCL (0.05). Based on Ann Arbor staging, incidence of DUSP22 gene rearrangement decreased as the clinical stage of ALK(-)ALCL increased (0.05). Incidence of TP63 gene rearrangement cases increases in patients at more advanced clinical stage(0.05). The five-year survival rate and prognosis of patients with DUSP22(+)ALK(-)ALCL were the highest. Patients with TP63(+) ALK(-)ALCL had the lower five-year survival and the worse prognosis (0.05). Presences of DUSP22 and TP63 chromosomal translocations correlate with the clinical stages and prognosis of ALK(-)ALCL and may be used for the differential diagnosis, determination of tumor aggressiveness and prognostication of ALK(-)ALCL.
探讨双特异性磷酸酶22（DUSP22）或p63基因（TP63）染色体易位与间变性淋巴瘤激酶阴性间变性大细胞淋巴瘤（ALK-ALCL）临床意义的相关性。选取2004年1月至2014年1月在福建省立医院收治的32例ALK-ALCL患者，采用荧光原位杂交（FISH）技术检测DUSP22和TP63基因的染色体易位情况，并分析DUSP22和TP63基因染色体易位与ALK-ALCL临床病理参数的关系。32例ALK-ALCL患者中，7例（21.8%）存在DUSP22基因重排（DUSP22+ALK-ALCL）；3例（9.4%）存在TP63基因重排（TP63+ALK-ALCL）；22例（68.8%）DUSP22和TP63基因均无重排（DUSP22-TP63-ALK-ALCL）。DUSP22+ALK-ALCL患者年龄较轻，TP63+ALK-ALCL患者年龄较大，DUSP22-TP63-ALK-ALCL患者的平均年龄介于二者之间（P<0.05）。根据Ann Arbor分期，随着ALK-ALCL临床分期的增加，DUSP22基因重排的发生率降低（P<0.05）；TP63基因重排的发生率在临床分期较晚的患者中增加（P<0.05）。DUSP22+ALK-ALCL患者的5年生存率和预后最好，TP63+ALK-ALCL患者的5年生存率较低，预后较差（P<0.05）。DUSP22和TP63基因染色体易位与ALK-ALCL的临床分期和预后相关，可用于ALK-ALCL的鉴别诊断、肿瘤侵袭性判断及预后评估。
